ProKidney (PROK) | Stock Overview & Key Data
ProKidney Performance Comparison
Stock Range
Today's Range
Low: $2.69
High: $2.94
on October 3, 2025
52 Week Range
Low: $0.46
High: $7.13
on April 9, 2025
on July 9, 2025
All-Time High: $14.19 on March 13, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$806.3M
EPS
-0.56
P/E Ratio (TTM)
-4.42
Forward P/E
-5.45
P/B Ratio
1.06
PEG Ratio
0.24
Div. Yield
305.81%
ROE
-40.52%
Beta
1.775
Debt to Equity
1.30
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-17,967.87%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-25.30%
Return on Equity (TTM)
-40.52%
EBITDA
$-170.2M
Net Income (TTM)
$-72.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.00
Quarterly Revenue Growth (YoY)
-3.91%
Quarterly Earnings Growth (YoY)
N/A
Dividend Information
Last 12-Month Dividend
$2.63
Current Dividend Yield
305.81%
3-Year Average Dividend Yield
36.48%
3-Year Average Annual Dividend
$3.15
3-Year Total Dividends
$9.44
Ex-Dividend Date
February 14, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| ProKidney PROK | 806.33M Small-cap | 10.04% | 16.10% | 328.13% | 285.92% | 58.38% | 61.18% | -71.04% | -72.74% |
| Vertex VRTX | 103.40B Large-cap | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% | -11.42% | 36.61% | 49.40% |
| Regeneron REGN | 63.78B Large-cap | 6.40% | 6.42% | 9.62% | -1.74% | -16.11% | -40.76% | -16.94% | -0.34% |
| Vera Therapeutics VERA | 1.98B Small-cap | 6.88% | 31.27% | 25.58% | 32.54% | -28.58% | -26.20% | 51.00% | 162.09% |
| Dyne Therapeutics DYN | 1.95B Small-cap | -0.68% | -3.12% | 49.09% | 38.64% | -48.70% | -59.91% | 2.67% | -29.94% |
| Liquidia LQDA | 1.93B Small-cap | 2.89% | -23.24% | 84.00% | 58.74% | 85.37% | 101.17% | 312.32% | 316.91% |
Ownership & Short Interest
Insider Ownership
26.62%
Institutional Ownership
30.44%
Shares Short
10M
Short Ratio
4.23
Short % of Shares Outstanding
10.50%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PROK's 52-week high and low?
- In the last 52 weeks, ProKidney reached a high of $7.13 (on July 9, 2025) and a low of $0.46 (on April 9, 2025).
- What is the market cap and P/E ratio for PROK?
- Curious about ProKidney's size and valuation? Its market capitalization stands at 806.33M. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.42, and the forward P/E (looking ahead) is -5.45.
- Does PROK pay dividends? If so, what's the yield?
- Yes, ProKidney is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 305.81%, and the company has paid an average of $3.15 per share annually over the past 3 years.
- Who are ProKidney's main competitors or similar companies to consider before investing?
When looking at ProKidney, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -11.42% 36.61% Regeneron
REGN63.78B Healthcare Biotechnology -40.76% -16.94% Vera Therapeutics
VERA1.98B Healthcare Biotechnology -26.20% 51.00% Dyne Therapeutics
DYN1.95B Healthcare Biotechnology -59.91% 2.67% Liquidia
LQDA1.93B Healthcare Biotechnology 101.17% 312.32% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for ProKidney Corp? (e.g., ROE, Debt/Equity)
- To get a sense of ProKidney's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -40.52%, the Debt to Equity ratio from the most recent quarter is 1.30, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PROK?
- Looking at ProKidney's growth, its revenue over the trailing twelve months (TTM) was $527K. Compared to the same quarter last year (YoY), quarterly revenue grew by -3.91%, and quarterly earnings saw a YoY growth of N/A.
- How much of PROK stock is held by insiders and institutions?
- Wondering who owns ProKidney stock? Company insiders (like executives and directors) hold about 26.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.44%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.